ABCL
Price
$3.62
Change
-$0.35 (-8.82%)
Updated
Nov 13 closing price
Capitalization
1.08B
102 days until earnings call
Intraday BUY SELL Signals
CYBN
Price
$5.94
Change
-$0.52 (-8.05%)
Updated
Nov 13 closing price
Capitalization
322.55M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs CYBN

Header iconABCL vs CYBN Comparison
Open Charts ABCL vs CYBNBanner chart's image
AbCellera Biologics
Price$3.62
Change-$0.35 (-8.82%)
Volume$7.11M
Capitalization1.08B
Cybin
Price$5.94
Change-$0.52 (-8.05%)
Volume$1.14M
Capitalization322.55M
ABCL vs CYBN Comparison Chart in %
View a ticker or compare two or three
VS
ABCL vs. CYBN commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and CYBN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ABCL: $3.62 vs. CYBN: $5.94)
Brand notoriety: ABCL and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 130% vs. CYBN: 131%
Market capitalization -- ABCL: $1.08B vs. CYBN: $322.55M
ABCL [@Biotechnology] is valued at $1.08B. CYBN’s [@Biotechnology] market capitalization is $322.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, CYBN is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while CYBN’s TA Score has 3 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 6 bearish.
  • CYBN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both ABCL and CYBN are a bad buy in the short-term.

Price Growth

ABCL (@Biotechnology) experienced а -20.09% price change this week, while CYBN (@Biotechnology) price change was -2.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 24, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.08B) has a higher market cap than CYBN($323M). ABCL YTD gains are higher at: 23.549 vs. CYBN (-32.653). CYBN has higher annual earnings (EBITDA): -152.51M vs. ABCL (-197.92M). ABCL has more cash in the bank: 553M vs. CYBN (119M). CYBN has less debt than ABCL: CYBN (44.5M) vs ABCL (142M). ABCL has higher revenues than CYBN: ABCL (32.9M) vs CYBN (0).
ABCLCYBNABCL / CYBN
Capitalization1.08B323M335%
EBITDA-197.92M-152.51M130%
Gain YTD23.549-32.653-72%
P/E RatioN/AN/A-
Revenue32.9M0-
Total Cash553M119M465%
Total Debt142M44.5M319%
FUNDAMENTALS RATINGS
CYBN: Fundamental Ratings
CYBN
OUTLOOK RATING
1..100
79
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLCYBN
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 18 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
CYBN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAIGF10.900.15
+1.40%
AIA Group, Ltd.
AHFCF0.57N/A
N/A
Flow Cap Corp.
RHCGF1.75N/A
N/A
Ryman Healthcare Ltd.
VMTHF0.31N/A
N/A
VENUS MEDTECH HANGZHOU INC.
NIABY4.04-0.07
-1.70%
Nibe Industrier AB

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
-8.82%
RXRX - ABCL
59%
Loosely correlated
-6.88%
CRSP - ABCL
59%
Loosely correlated
-2.07%
ABSI - ABCL
56%
Loosely correlated
-22.35%
VCYT - ABCL
56%
Loosely correlated
-5.74%
BEAM - ABCL
52%
Loosely correlated
-0.96%
More

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-8.05%
ATAI - CYBN
40%
Loosely correlated
-4.62%
ABSI - CYBN
35%
Loosely correlated
-22.35%
RXRX - CYBN
35%
Loosely correlated
-6.88%
ABCL - CYBN
33%
Poorly correlated
-8.82%
EYPT - CYBN
33%
Poorly correlated
-4.00%
More